Profilin-1 is involved in macroangiopathy induced by advanced glycation end products via vascular remodeling and inflammation

Figure 5 Effect of advanced glycation end products on the proliferation of cultured rat aortic vascular smooth muscle cells (n = 6). A: MTT detection of the effect of incubation with advanced glycation end products (AGEs) (0, 50, 100, 150, 200, or 400 µg/mL) for different times (0, 24, 48, or 72 h) on rat aortic vascular smooth muscle cell (RASMC) proliferation. ^aP < 0.05 for the comparison of the 24 h control group with the control group, ^cP < 0.05 for the comparison of the 48 h control group with the control group, ^eP < 0.05 for the comparison of the 72 h control group with the control group; B: Proliferation of RASMCs treated with AGEs (0, 50, 100, 150, 200, or 400 µg/mL) for 24 h quantified using flow cytometry. Data were obtained from six independent experiments (n = 6); C: EdU staining showing the effect of incubation with AGEs (0, 50, 100, 150, 200, or 400 µg/mL) for 24 h on RASMC proliferation; D: Proliferation of RASMCs treated with AGEs (0, 50, 100, 150, 200, or 400 µg/mL) for 24 h quantified using fluorescence microscopy. ^gP < 0.05 compared with the control group. ^hP < 0.01 compared with the control group. EdU: 5-ethynyl-2-deoxyuridine.